GlassScriptPhysician profile
Brandy D Ballard
NPI 1174621478
$1,846.11
in general payments reported to CMS, 2019-2025
26 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $279 · 2023: $548 · 2024: $348 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $562.54 | 2021-2025 | |
| Novo Nordisk INC | $283.28 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $223.82 | 2021-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $96.98 | 2021-2023 | Jardiance |
| Pfizer INC. | $91.72 | 2021-2025 | |
| Amgen INC. | $70.37 | 2021-2024 | Repatha, Otezla |
| Qorumpartners | $69.64 | 2022 | |
| Exact Sciences Corporation | $49.12 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.30 | 2023-2025 | Caplyta |
| Eisai INC. | $37.46 | 2021 | |
| Glaxosmithkline, LLC. | $33.48 | 2023 | Trelegy Ellipta |
| Genzyme Corporation | $30.36 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.48 | 2023 | |
| Optos, INC. | $24.12 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.44 | 2023 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $19.89 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $19.76 | 2021 | |
| Phadia US INC. | $19.67 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.93 | 2024 | Fanapt |
| Redhill Biopharma INC. | $17.84 | 2021 | |
| Daiichi Sankyo INC. | $17.51 | 2021 | |
| Medtronic, INC. | $16.11 | 2021 | |
| Sanofi Pasteur INC. | $15.07 | 2021 | |
| Genentech USA, INC. | $12.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.28 | 2021 | |
| Amarin Pharma, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.